The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

References

• Hardee ME, Cao Y, Fu P, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2007;2:e549.
   PubMed Web of Science ®Google Scholar
• Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021–9.
   PubMed Web of Science ®Google Scholar
• Chan KK, Matchett KB, Coulter JA, et al. Erythropoietin drives breast cancer progression by activation of its receptor EPOR. Oncotarget 2017;8:38251–63.
   PubMedGoogle Scholar
• Zhou B, Damrauer JS, Bailey ST, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest 2014;124:553–63.
   PubMed Web of Science ®Google Scholar
• Merkle R, Steiert B, Salopiata F, et al. Identification of cell type-specific differences in erythropoietin receptor signaling in primary erythroid and lung cancer cells. PLoS Comput Biol 2016;12:e1005049.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Dibirdik I, Qazi S, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 2007;15:800–14.
   PubMed Web of Science ®Google Scholar
• Kokabee L, Wang X, Sevinsky CJ, et al. Bruton’s tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther 2015;16:1604–15.
   PubMed Web of Science ®Google Scholar
• Guo W, Liu R, Bhardwaj G, et al. Targeting BTK/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis 2014;5:e1409.
   PubMed Web of Science ®Google Scholar
• Sahin K, Tuzcu M, Yabas M, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs 2018;36:388–95.
   PubMed Web of Science ®Google Scholar
• Aalipour A, Advani RH. Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol 2014;5:121–33.
   PubMedGoogle Scholar
• de Rooij M, Kuil A, Geest C, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590–4.
   PubMed Web of Science ®Google Scholar
• Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2014;28:649–57.
   PubMed Web of Science ®Google Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 2018;17:57.
   PubMed Web of Science ®Google Scholar
• Wang X, Wong J, Sevinsky CJ, et al. Bruton’s tyrosine kinase inhibitors prevent therapeutic Escape in breast cancer cells. Mol Cancer Ther 2016;15:2198–208.
   PubMed Web of Science ®Google Scholar
• Zucha MA, Wu AT, Lee WH, et al. Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget 2015;6:13255–68.
   PubMedGoogle Scholar
• Feldman L, Wang Y, Rhim J, et al. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006;66:135–45.
   PubMed Web of Science ®Google Scholar
• Vijayan V, Baumgart-Vogt E, Naidu S, et al. Bruton’s tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages. J Immunol 2011;187:817–27.
   PubMed Web of Science ®Google Scholar
• Uckun FM. Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases. Cell Cycle 2007;6:3021–6.
   PubMed Web of Science ®Google Scholar
• Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647–57.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
   PubMedGoogle Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Tankiewicz-Kwedlo A, Hermanowicz JM, Pawlak K, et al. Erythropoietin intensifies the proapoptotic activity of LFM-A13 in cells and in a mouse model of colorectal cancer. Int J Mol Sci 2018;23:19.
   Google Scholar
• Tankiewicz-Kwedlo A, Hermanowicz JM, Domaniewski T, et al. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer. Br J Pharmacol 2018;175:743–62.
   PubMed Web of Science ®Google Scholar
• Zhao C, Wang X, Zhao Y, et al. A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. PLoS One 2011;6:e21768.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Mori K, Ichinose S, et al. In vitro and in vivo characterization of iris pigment epithelial cells cultured on amniotic membranes. Mol Vis 2006;12:1022–32.
   PubMed Web of Science ®Google Scholar
• Jalalie L, Rezaie MJ, Jalili A, et al. Distribution of the CM-Dil-Labeled human umbilical cord vein mesenchymal stem cells migrated to the cyclophosphamide-injured ovaries in C57BL/6 mice. Iran Biomed J 2019;23:200–8.
   PubMedGoogle Scholar
• Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. 4th ed. Lyon, ‎France: IARC Press; 2012.
   Google Scholar
• He W, Zhang A, Qi L, et al. FOXO1, a potential therapeutic target, regulates autophagic flux, oxidative stress, mitochondrial dysfunction, and apoptosis in human cholangiocarcinoma QBC939 cells. Cell Physiol Biochem 2018;45:1506–14.
   PubMedGoogle Scholar
• Lehn S, Tobin NP, Berglund P, et al. Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol 2010;177:2886–97.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–16.
   PubMed Web of Science ®Google Scholar
• van den Akker E, van Dijk TB, Schmidt U, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem 2004;385:409–13.
   PubMed Web of Science ®Google Scholar
• La Rosa S, Rubbia-Brandt L, Scoazec JY, Weber A. Editorial: tumor heterogeneity. Front Med (Lausanne) 2019;6:156.
   PubMed Web of Science ®Google Scholar
• Novero A, Ravella PM, Chen Y, et al. Ibrutinib for B cell malignancies. Exp Hematol Oncol 2014;3:4.
   PubMedGoogle Scholar
• Eifert C, Wang X, Kokabee L, et al. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer 2013;52:961–75.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Cao Q, Zhang Y, Su D. Activation and regulation of caspase-6 and its role in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 2015;55:553–72.
   PubMed Web of Science ®Google Scholar
• Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002;9:1046–56.
   PubMed Web of Science ®Google Scholar
• Alao JP, Gamble SC, Stavropoulou AV, et al. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 2006;5:7.
   PubMed Web of Science ®Google Scholar
• Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:24.
   PubMed Web of Science ®Google Scholar
• Alao JP, Lam EW, Ali S, et al. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 2004;10:8094–104.
   PubMed Web of Science ®Google Scholar
• Fen Q, Sekula D, Müller R, et al. Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene 2007;26:5098–106.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kim J. PLK-1 targeted inhibitors and their potential against tumorigenesis. Biomed Res Int 2015;2015:705745.
   PubMed Web of Science ®Google Scholar